Max Duckworth

FAR Biotech is a preclinical, computational drug discovery company that focuses on hard-to-drug targets that have high scientific and commercial value. Founded by Dr Martin Martinov after 25 years in academia and industry -- and named after the Bulgarian word “far” that translates into “lighthouse” or “beacon” -- FAR seeks to shine a light on drug discovery in areas of high unmet clinical need. FAR's proprietary technology can more rapidly identify novel, structurally diverse, optimized, lead molecules that other approaches would not look for, let alone find. The key differentiator is FAR's complete and rigorous quantum mechanical representation of drug-target interactions -- which embeds the advantages of quantum similarity and multi-property optimization for hit and lead identification -- augmented by AI / machine learning & big data. FAR's quantum biomodelling platform has been validated preclinically across a number of therapeutic areas, including neurodegeneration, oncology and infectious diseases.